About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/04/2020.
  • B-Cell Differentiation (CD19)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    CD19 is a surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that can act as a central positive response regulator in B cells.1-3 CD19 is expressed during normal B-cell development, and the expression is maintained following malignant transformation of B cells.2-4 The specific expression of CD19 in B-cell lineage lymphomas and leukemias makes CD19 a promising target antigen in B-cell malignancies, like non-Hodgkin lymphomas, through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy.2-4

    View Related Molecules

    References

    1. Scheuermann RH and Racila E. Leuk Lymphoma. 1995;18:385-397. PMID: 8528044
    2. Wang K, et al. Exp Hematol Oncol. 2012;1:36. PMID: 23210908
    3. Naddafi R, Davami F. IJMCM. 2015;4:143-151. PMID: 26629482
    4. Maude SL, et al. Blood. 2015;125:4017-4023. PMID: 25999455